Did the introduction of varenicline in England substitute for or add to the use of other smoking cessation medications?

Nicotine and Tobacco Research

Volumn 13, Issue 9, 2011, Pages 793-799

  Kotz, Daniel ^a,b   Fidler, Jennifer A ^b   West, Robert ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; NICOTINE PATCH; NON PRESCRIPTION DRUG; VARENICLINE;

ADULT; ARTICLE; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NICOTINE REPLACEMENT THERAPY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; SMOKING CESSATION; TOBACCO DEPENDENCE; UNITED KINGDOM;

EID: 80052748914     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntr075     Document Type: Article

References (22)

1. ACORN. (2010). New ACORN classification map. Retrieved from www.caci.co.uk/acorn/acornmap.asp.
2. Aubin, H. J., Bobak, A., Britton, J. R., Oncken, C., Billing, C. B., Jr., Gong, J., et al. (2008). Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax, 63, 717-724. doi:10.1136/thx.2007.090647.
3. Cahill, K., Stead, L. F., & Lancaster, T. (2008). Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews, (3). Retrieved from http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD006103/frame.htmldoi:10.1002/14651858.CD006103.pub3.
4. Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel. (2008). A clinical practice guideline for treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. American Journal of Preventive Medicine, 35, 158-176. doi:10.1016/j.amepre.2008.04.009.
5. Fiore, M. C., Jaén, C. R., Baker, T. B., Bailey, W. C., Benowitz, N. L., Curry, S. J., et al. (2008). Treating tobacco use and dependence: 2008 update. Rockville, MD: U.S. Department of Health and Human Services.
6. Gonzales, D., Rennard, S. I., Nides, M., Oncken, C., Azoulay, S., Billing, C. B., et al. (2006). Varenicline, an alpha4-beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association, 296, 47-55.
7. Green, L. W., Ottoson, J. M., Garcia, C., & Hiatt, R. A. (2009). Diffusion theory and knowledge dissemination, utilization, and integration in public health. Annual Review of Public Health, 30, 151-174. doi:10.1146/annurev.publhealth.031308.100049.
8. Gunnell, D., Irvine, D., Wise, L., Davies, C., & Martin, R. M. (2009). Varenicline and suicidal behaviour: A cohort study based on data from the general practice research database. British Medical Journal, 339, b3805. doi:10.1136/bmj.b3805.
9. Hackshaw, L., McEwen, A., West, R., & Bauld, L. (2010). Quit attempts in response to smoke-free legislation in England. Tobacco Control, 19, 160-164. doi:10.1136/tc.2009.032656.
10. Heatherton, T. F., Kozlowski, L. T., Frecker, R. C., & Fagerstrom, K. O. (1991). The Fagerström Test for Nicotine Dependence: A revision of the Fagerström Tolerance Questionnaire. British Journal of Addiction, 86, 1119-1127.
11. Hughes, J. R. (2008). Smoking and suicide: A brief overview. Drug Alcohol Depend, 98, 169-178. doi:10.1016/j.drugalcdep.2008.06.003.
12. Hughes, J. R., Stead, L. F., & Lancaster, T. (2004). Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews, (4). doi:10.1002/14651858.CD000031.pub3.
13. Hyland, A., Rivard, C., Fong, G. T., Hammond, D., Hastings, G., McNeill, A., et al. (2009, April). Use of stop smoking medications before and after the introduction of varenicline in the US and the UK: Findings from the International Tobacco Control (ITC) Four Country Survey. Paper presented at the Annual conference of the Society for Research on Nicotine and Tobacco, Dublin.
14. Keating, G. M., & Lyseng-Williamson, K. A. (2010). Varenicline: A pharmacoeconomic review of its use as an aid to smoking cessation. Pharmacoeconomics, 28, 231-254.
15. Kotz, D., Fidler, J., & West, R. (2009). Factors associated with the use of aids to cessation in English smokers. Addiction, 104, 1403-1410. doi:10.1111/j.1360-0443.2009.02639.x.
16. Langley, T. E., Huang, Y., McNeill, A., Coleman, T., Szatkowski, L., & Lewis, S. (2011). Prescribing of smoking cessation medication in England since the introduction of varenicline. Addiction. Advance online publication. doi:10.1111/j.1360-0443.2011.03426.xi.
17. National Institute for Health and Clinical Excellence. (2007). NICE technology appraisal guidance 123. Varenicline for smoking cessation. London: National Institute for Health and Clinical Excellence.
18. Raw, M., Regan, S., Rigotti, N. A., & McNeill, A. (20019). A survey of tobacco dependence treatment guidelines in 31 countries. Addiction, 104, 1243-1250. doi:10.1111/j.1360-0443.2009.02584.x.
19. Smoking In England. (2010). Up-to-date information on smoking and smoking cessation in England. Retrieved from www.smokinginengland.info.
20. Stead, L. F., Perera, R., Bullen, C., Mant, D., & Lancaster, T. (2008). Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, (1). doi:10.1002/14651858.CD000146.pub3.
21. U.S. Food and Drug Administration. (2008). Varenicline (marketed as Chantix) information, FDA ALERT [2/1/2008] Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm106540.htm.
22. West, R., DiMarino, M. E., Gitchell, J. G., & McNeill, A. (2005). Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tobacco Control, 14, 166-171. doi:10.1136/tc.2004.008649.